The Motley Fool article’s author favors Vertex Pharmaceuticals over CRISPR Therapeutics for 2026, citing Vertex’s nearly $12.1 billion in FY2025 revenue and 32.7% net margin, versus CRISPR’s approximately $581.6 million loss as it invests in research.
CRISPR’s FY2025 revenue was nearly $3.5 million, down 90%; the article says earlier periods included large one-time partner milestone payments. CRISPR’s free cash flow was negative $345.9 million, while Vertex’s was close to $3.2 billion; Vertex revenue grew about 9.6% year over year.
Vertex’s case rests on its cystic-fibrosis business, a pain drug gaining commercial traction, expanding CASGEVY use and a recently acquired kidney-disease drug awaiting an FDA decision the article calls imminent. The analysis says CRISPR relies on Vertex for CASGEVY commercialization and manufacturing, may need more capital, and faces a ToolGen patent-infringement lawsuit filed in late 2025. Its FMP-sourced valuation table, which may differ from other providers, lists price-to-sales ratios of 402.6x for CRISPR and 10.7x for Vertex; forward P/E is unavailable for CRISPR and 39.9x for Vertex.
